United Therapeutics Co. (NASDAQ:UTHR) Director Christopher Causey Sells 2,240 Shares of Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Christopher Causey sold 2,240 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $259.91, for a total value of $582,198.40. Following the transaction, the director now owns 4,185 shares of the company’s stock, valued at approximately $1,087,723.35. The transaction was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Trading Down 0.7 %

UTHR opened at $260.51 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.64 and a current ratio of 3.77. The stock’s 50 day moving average price is $236.86 and its 200-day moving average price is $229.35. United Therapeutics Co. has a one year low of $204.44 and a one year high of $264.85. The stock has a market cap of $11.56 billion, a price-to-earnings ratio of 12.32 and a beta of 0.54.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating the consensus estimate of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The company had revenue of $677.70 million for the quarter, compared to the consensus estimate of $620.31 million. During the same quarter in the prior year, the company posted $4.86 EPS. United Therapeutics’s quarterly revenue was up 33.7% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics Co. will post 23.88 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Rise Advisors LLC purchased a new stake in United Therapeutics in the 1st quarter valued at about $32,000. GAMMA Investing LLC bought a new position in United Therapeutics in the fourth quarter worth approximately $43,000. Benjamin F. Edwards & Company Inc. grew its stake in United Therapeutics by 63.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 117 shares in the last quarter. C M Bidwell & Associates Ltd. purchased a new position in United Therapeutics during the 3rd quarter worth $91,000. Finally, Janiczek Wealth Management LLC raised its position in United Therapeutics by 21.1% during the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 84 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on UTHR. StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. Wedbush restated an “outperform” rating and issued a $308.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. Leerink Partnrs restated an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. SVB Leerink began coverage on United Therapeutics in a research report on Monday, February 5th. They issued an “outperform” rating and a $330.00 price target for the company. Finally, Wells Fargo & Company upped their price objective on United Therapeutics from $309.00 to $325.00 and gave the company an “overweight” rating in a research report on Thursday, March 7th. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $308.78.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.